BioSpace News Archive

InMode Ltd., a leading global provider of innovative medical technologies, announced its consolidated financial results for the third quarter ended September 30, 2023.

Acurx Pharmaceuticals, Inc. announced efficacy results from the Phase 2 clinical trial of ibezapolstat for the treatment of C. difficile Infection.

Exscientia plc will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, before the open of U.S. markets.

Bicycle Therapeutics plc reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates.

AlloVir, Inc., a late-clinical stage allogeneic T cell immunotherapy company, reported financial results from the third quarter ended September 30, 2023.

ANGANY announces the appointment of Christine Guillen, PharmD, as Chief Executive Officer.

Seres Therapeutics, Inc., a leading microbiome therapeutics company, reported financial results for the third quarter ended September 30, 2023, including VOWST net sales of $7.6 million.

Cognition Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023 and provided recent business updates.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that Tim Dyer, Chief Executive Officer, and Dr. Mikhail Kalinichev, Head of Translational Science, will be attending the Bio-Europe 2023 Conference in Munich, Germany.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2023, and provides a corporate update.